Phase 2, Phase 3 Recruiting NIH
This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer f…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05987241
Sites in California: - Kaiser Permanente-Anaheim — Anaheim, California
- Kaiser Permanente-Baldwin Park — Baldwin Park, California
- Kaiser Permanente-Bellflower — Bellflower, California
- Kaiser Permanente Dublin — Dublin, California
- Kaiser Permanente-Fontana — Fontana, California
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of decreased number of radiation (ultra-hypofractionated) treatments to the usual radiation number of treatments (hypofractionation) with standard of care chemotherapy, with cisplatin, gemcitabine o…
Sponsor: NRG Oncology
NCT ID: NCT07097142
Sites in California: - UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
- UC San Diego Moores Cancer Center — La Jolla, California
- UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
- University of California Davis Comprehensive Cancer Center — Sacramento, California
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding gemcitabine to intravesical Bacillus Calmette Guerin (BCG) versus intravesical BCG alone in patients with non-muscle invasive bladder cancer that has come back after a period of improvemen…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07000084
Sites in California: - UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
- UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
Phase 3 Recruiting Industry
The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread. Vepugratinib or placebo will be administered in c…
Sponsor: Eli Lilly and Company
NCT ID: NCT07218380
Sites in California: - Chao Family Comprehensive Cancer Center and Ambulatory Care (CIACC) - Irvine — Irvine, California
- TRIO-US (Translational Research in Oncology-US) — Los Angeles, California
- UCLA Hematology/Oncology - Santa Monica — Los Angeles, California
- University of California, Irvine (UCI) Health - UC Irvine Medical Center — Orange, California
- University of California Davis (UC Davis) Comprehensive Cancer Center — Sacramento, California
Phase 3 Recruiting Industry
A phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)
Sponsor: Ferring Pharmaceuticals
NCT ID: NCT06510374
Sites in California: - Urology Associates of Central California — Fresno, California
- American Institute of Research — Los Angeles, California
- Urology Center of Southern California — Murrieta, California
- University of California, Irvine — Orange, California
- Providence Saint John's Cancer Institute — Santa Monica, California
Phase 3 Recruiting Industry
The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06319820
Sites in California: - Genesis Research LLC — Los Alamitos, California
- USC Norris Comprehensive Cancer Center — Los Angeles, California
- University of California Irvine Medical Center — Orange, California
- Om Research LLC — San Diego, California
- Genesis Research LLC 1 — Sherman Oaks, California
Phase 2, Phase 3 Recruiting Industry
A Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or After Immunotherapy
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07106762
Sites in California: - Local Institution - 0162 — Fullerton, California
- Local Institution - 0252 — Palo Alto, California
- Local Institution - 0163 — Sacramento, California
- University of California Davis (UC Davis) Comprehensive Cancer Center — Sacramento, California
- Local Institution - 0251 — San Francisco, California
Phase 3 Recruiting Industry
The pivotal phase 3 trial (rAd-IFN-CS 003) evaluating the efficacy of nadofaragene firadenovec showed that 55 (53.4%) of 103 subjects with CIS ± high-grade Ta/T1 achieved a complete response (CR) at 3 months. In this trial, the safety and …
Sponsor: Ferring Pharmaceuticals
NCT ID: NCT06545955
Sites in California: - American Institute of Research — Los Angeles, California
- USC Kenneth Norris Jr Cancer Hospital — Los Angeles, California
- University of California, Irvine — Orange, California
- Genesis Research, LLC - San Diego — San Diego, California
Phase 2, Phase 3 Recruiting Industry
This is a global, multicenter, randomized, open-label, Phase 2/3 study of Dato-DXd plus carboplatin or cisplatin versus gemcitabine plus carboplatin or cisplatin in participants with la/mUC who progressed during or after EV plus pembrolizu…
Sponsor: Daiichi Sankyo
NCT ID: NCT07129993
Sites in California: - Research Site — Fullerton, California
- Research Site — La Jolla, California
- Research Site — San Francisco, California
Phase 3 Recruiting Academic/Other
The present study evaluates empty and full bladder protocols for radiation therapy of genitourinary (GU), gynecological (Gyn), and gastrointestinal (GI) malignancies of the pelvis.
Sponsor: University of California, San Diego
NCT ID: NCT06651697
Sites in California: - University of California, San Diego — San Diego, California
Phase 2, Phase 3 Recruiting Industry
Patients with solid tumors that have high expression levels of EphrinB2 are treated with regimens that include EphrinB2 inhibitor, sEphB4-HSA. The primary objective of this study is to demonstrate additive therapeutic benefit for sEphB4-HS…
Sponsor: Vasgene Therapeutics, Inc
NCT ID: NCT06493552
Sites in California: - Sarcoma Oncology Center — Santa Monica, California
Phase 2 Recruiting NIH
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in California: - Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
- PCR Oncology — Arroyo Grande, California
- Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
- Community Cancer Institute — Clovis, California
- University Oncology Associates — Clovis, California
Phase 2 Recruiting Industry
This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants. Participants will have cancer that …
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT04879329
Sites in California: - Kaiser Permanente Anaheim Kraemer Medical Offices — Anaheim, California
- Foothill Cardioology — Arcadia, California
- Kaiser Permanente Baldwin Park Medical Center — Baldwin Park, California
- Kaiser Permanente Bellflower Medical Offices — Bellflower, California
- Beverly Hills Multi-Specialties Practice — Beverly Hills, California
Phase 2 Recruiting NIH
This phase II trial tests the effect of giving pembrolizumab in combination with radiation therapy after chemotherapy in preventing surgery to remove the bladder in patients with muscle invasive bladder cancer. Standard of care therapy inc…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07061964
Sites in California: - Tower Cancer Research Foundation — Beverly Hills, California
- City of Hope Corona — Corona, California
- City of Hope Comprehensive Cancer Center — Duarte, California
- City of Hope at Irvine Lennar — Irvine, California
- City of Hope Antelope Valley — Lancaster, California
Phase 2 Recruiting NIH
This phase II trial compares the use of pembrolizumab and radiation therapy to chemotherapy with cisplatin, gemcitabine, 5-fluorouracil or mitomycin-C and radiation therapy for the treatment of non-muscle invasive bladder cancer. Immunothe…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06770582
Sites in California: - AIS Cancer Center at San Joaquin Community Hospital — Bakersfield, California
- Los Angeles General Medical Center — Los Angeles, California
- USC / Norris Comprehensive Cancer Center — Los Angeles, California
Phase 2 Recruiting Industry
This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer.
Sponsor: CG Oncology, Inc.
NCT ID: NCT06567743
Sites in California: - Michael G Oefelein, MD Clinical Trials — Bakersfield, California
- Genesis Research (Greater Los Angeles) — Los Alamitos, California
- Advanced Urology — Los Angeles, California
- Urology Center of Southern California — Murrieta, California
- University of California, Irvine — Orange, California
Phase 1, Phase 2 Recruiting Industry
This study will evaluate the safety and efficacy of intravesical administration of EG-70 in the bladder and its effect on bladder tumors in patients with NMIBC. This study study consists of two phases; a Phase 1 dose-escalation to establis…
Sponsor: enGene, Inc.
NCT ID: NCT04752722
Sites in California: - University of California - Irvine Medical Center — Irvine, California
- UC San Diego Moores Cancer Center — La Jolla, California
- USC/Norris Comprehensive Cancer Center — Los Angeles, California
- Tower Urology — Los Angeles, California
- Genesis Research — San Diego, California
Phase 2 Recruiting Industry
TARA-002-101-Ph2 is an open-label study to investigate the safety and efficacy of intravesical instillation of TARA-002 in adults 18 years of age or older with high-grade CIS NMIBC (± Ta/T1). The purpose of this Phase 2 study (TARA-002-101…
Sponsor: Protara Therapeutics
NCT ID: NCT05951179
Sites in California: - Michael Oefelein Clinical Trials — Bakersfield, California
- Urology Group of Southern California — Los Angeles, California
- University of California Irvine Medical Center — Orange, California
- Genesis Research — San Diego, California
- Genesis Research LLC — Torrance, California
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in California: - University of California Irvine Chao Family Comprehensive Cancer Center — Irvine, California
- University of San Diego Moores Cancer Center — La Jolla, California
- UCLA Jonsson Comprehensive Cancer Center — Los Angeles, California
- USC Norris Comprehensive Cancer Center — Los Angeles, California
Phase 1, Phase 2 Recruiting Industry
The purpose of the study in Part 1 (dose escalation) and in Part 2 (dose expansion) is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) and evaluate preliminary clinical efficacy. Part 3 (dose expansion) will confirm safety and pre…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT05316155
Sites in California: - University of Southern California — Los Angeles, California
Phase 2 Recruiting Industry
Phase 2 Study of TYRA-300 in FGFR3 Altered Low Grade, Intermediate Risk NMIBC
Sponsor: Tyra Biosciences, Inc
NCT ID: NCT06995677
Sites in California: - Tri Valley Urology - Murrieta — Murrieta, California
- Om Research LLC — San Diego, California
Phase 2 Recruiting Industry
Researchers are looking for new ways to treat people with high-risk non-muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder but has not spread to the bladder muscle or outside of th…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06833073
Sites in California: - Michael G Oefelein Clinical Trials ( Site 0138) — Bakersfield, California
- Genesis Research, LLC ( Site 0141) — Los Alamitos, California
- USC Norris Comprehensive Cancer Center ( Site 0123) — Los Angeles, California
- Genesis Healthcare-Torrance ( Site 0140) — Torrance, California
- Genesis Research LLC ( Site 0118) — Torrance, California
Phase 1, Phase 2 Recruiting Industry
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-ri…
Sponsor: Marengo Therapeutics, Inc.
NCT ID: NCT05592626
Sites in California: - Loma Linda University Cancer Center — Loma Linda, California
- UC Davis Comprehensive Cancer Center — Sacramento, California
Phase 2 Recruiting Industry
This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carc…
Sponsor: Daiichi Sankyo
NCT ID: NCT06172478
Sites in California: - City of Hope — Duarte, California
Phase 1, Phase 2 Recruiting Academic/Other
Upon successful screening and registration, enrollment to durvalumab monotherapy (cohort 1) will begin. If DLT criteria outlined in the protocol are exceeded with durvalumab monotherapy (cohort 1), the study will close. Provided the safety…
Sponsor: Noah Hahn, M.D.
NCT ID: NCT03317158
Sites in California: - Stanford University — Stanford, California